Top News
Latest News
PARTNERSHIPS
31 Mar 2026
The Shot Is So Last Year. Lilly Wants You to Pop a PillREGULATORY
26 Mar 2026
Wegovy Turns Up the Dial and Takes Aim at LillyINVESTMENT
23 Mar 2026
Oral Obesity Pill Push Draws $287M BetPARTNERSHIPS
17 Mar 2026
Why Novo Nordisk Is Putting $2 Billion Into a Pill
Medicare's GLP-1 Bridge: Who Gets In?
REGULATORY
12 Mar 2026
Medicare launches a temporary program giving eligible patients early, subsidized access to GLP-1 obesity drugs
INSIGHTS
8 Dec 2025
The Oral Bet Challenging Today’s GLP 1 Era
Aardvark and Rivus advance early stage metabolic therapies as interest grows beyond GLP 1 drugs and potential new options emerge
RESEARCH
5 Dec 2025
Oral Obesity Drug Fuels Competition in Metabolic Care
Lilly’s oral orforglipron heats up the race to reshape obesity and diabetes treatment
REGULATORY
4 Dec 2025
FDA Draft Sparks a Metabolic Shake Up
New FDA guidance pushes durability to the forefront as industry giants deepen their metabolic bets
INNOVATION
3 Dec 2025
AI Tools Stir Cautious Shift in US Metabolic Innovation Race
Firms explore AI to speed discovery as analysts note opportunity, uncertainty and a fluid competitive landscape
PARTNERSHIPS
2 Dec 2025
Metabolic Care Gets a National Wake Up Call
New US metabolic alliance pushes earlier care and integrated treatments; firms like Lilly and Novo Nordisk should prepare for shifting sta...
INVESTMENT
1 Dec 2025
A MASH Contender Puts Roche in the Spotlight
Roche’s move to acquire 89bio boosts a leading MASH therapy and opens new partnership opportunities across metabolic medicine
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.